Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily versus three-times-daily nystatin prophylaxis after kidney transplantation
IRCT20260804070532N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of nystatin in oral candidiasis (2 arms), sponsored by Urmia University of Medical Sciences. Primary endpoint: Oropharyngeal candidiasis. Started Aug 2025; status: completed.
02
Drugs
nystatin
03
Conditions
oral candidiasis
Beyond the preview
Go deeper on IRCT20260804070532N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260804070532N1.